Research programme: thrombosis therapy - Mitsubishi Tanabe Pharma
Alternative Names: TA-7182; Thrombosis therapy research programme - Mitsubishi Tanabe PharmaLatest Information Update: 27 May 2010
At a glance
- Originator Tanabe Seiyaku
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 27 May 2010 Discontinued - Preclinical for Thrombosis in Japan (unspecified route)
- 18 Jul 2005 This programme is available for licensing outside Japan (http://www.tanabe.co.jp)
- 18 Jul 2005 Preclinical trials in Thrombosis in Japan (unspecified route)